Debashis Ghosh
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1770 | 5.110 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 352 | 4.680 |
Why?
| | Models, Statistical | 44 | 2024 | 667 | 4.620 |
Why?
| | Leishmaniasis, Visceral | 16 | 2024 | 22 | 4.470 |
Why?
| | Algorithms | 41 | 2025 | 1702 | 4.250 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 765 | 3.420 |
Why?
| | Machine Learning | 10 | 2024 | 496 | 2.710 |
Why?
| | Computer Simulation | 36 | 2024 | 986 | 2.690 |
Why?
| | Computational Biology | 20 | 2025 | 645 | 2.660 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.270 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1279 | 2.230 |
Why?
| | Metabolomics | 9 | 2022 | 679 | 2.210 |
Why?
| | Biometry | 13 | 2011 | 70 | 2.150 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 1034 | 1.870 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 18 | 1.790 |
Why?
| | Neoplasms | 25 | 2024 | 2666 | 1.730 |
Why?
| | Eye Proteins | 6 | 2016 | 92 | 1.720 |
Why?
| | Software | 15 | 2025 | 670 | 1.710 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.480 |
Why?
| | Regression Analysis | 13 | 2021 | 1029 | 1.470 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.470 |
Why?
| | Genomics | 12 | 2024 | 793 | 1.360 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 433 | 1.330 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1042 | 1.320 |
Why?
| | Models, Biological | 14 | 2021 | 1775 | 1.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1402 | 1.280 |
Why?
| | Humans | 196 | 2025 | 137514 | 1.230 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 434 | 1.150 |
Why?
| | Causality | 4 | 2022 | 127 | 1.150 |
Why?
| | Databases, Factual | 12 | 2024 | 1351 | 1.150 |
Why?
| | Biomarkers | 14 | 2021 | 4172 | 1.140 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1263 | 1.120 |
Why?
| | Insecticides | 4 | 2023 | 38 | 1.090 |
Why?
| | Insect Control | 4 | 2023 | 16 | 1.080 |
Why?
| | Biostatistics | 3 | 2014 | 17 | 1.080 |
Why?
| | Insect Vectors | 4 | 2023 | 37 | 1.070 |
Why?
| | Aromatase | 2 | 2019 | 32 | 1.020 |
Why?
| | Bangladesh | 13 | 2024 | 56 | 1.010 |
Why?
| | Survival Analysis | 12 | 2024 | 1320 | 1.010 |
Why?
| | Endemic Diseases | 2 | 2024 | 32 | 1.010 |
Why?
| | Natural Gas | 1 | 2025 | 24 | 0.930 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 179 | 0.930 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 31 | 0.930 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 292 | 0.910 |
Why?
| | Microscopy | 3 | 2023 | 144 | 0.890 |
Why?
| | Magnetoencephalography | 2 | 2021 | 149 | 0.870 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.860 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 258 | 0.850 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.840 |
Why?
| | Environmental Exposure | 3 | 2025 | 575 | 0.810 |
Why?
| | Genetic Association Studies | 5 | 2019 | 377 | 0.800 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2494 | 0.800 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1524 | 0.800 |
Why?
| | Models, Genetic | 11 | 2019 | 607 | 0.790 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 287 | 0.790 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 451 | 0.780 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 309 | 0.770 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 386 | 0.760 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.750 |
Why?
| | Connectome | 2 | 2021 | 91 | 0.740 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 35 | 0.720 |
Why?
| | Mass Spectrometry | 6 | 2022 | 741 | 0.720 |
Why?
| | Brain | 4 | 2024 | 2831 | 0.690 |
Why?
| | Nitriles | 1 | 2021 | 175 | 0.690 |
Why?
| | Propensity Score | 4 | 2018 | 288 | 0.690 |
Why?
| | Housing | 2 | 2021 | 146 | 0.690 |
Why?
| | Endpoint Determination | 2 | 2011 | 77 | 0.690 |
Why?
| | Cluster Analysis | 12 | 2024 | 502 | 0.680 |
Why?
| | Brain Mapping | 2 | 2021 | 610 | 0.680 |
Why?
| | Feasibility Studies | 2 | 2024 | 950 | 0.680 |
Why?
| | Phenotype | 12 | 2023 | 3205 | 0.650 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1047 | 0.650 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 159 | 0.640 |
Why?
| | Risk Assessment | 8 | 2020 | 3439 | 0.630 |
Why?
| | Placenta | 2 | 2019 | 754 | 0.630 |
Why?
| | Image Processing, Computer-Assisted | 7 | 2024 | 784 | 0.630 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 107 | 0.630 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 339 | 0.630 |
Why?
| | Databases, Genetic | 11 | 2021 | 237 | 0.630 |
Why?
| | Learning | 1 | 2023 | 430 | 0.620 |
Why?
| | Genetic Variation | 4 | 2019 | 986 | 0.610 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 126 | 0.610 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 185 | 0.600 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.580 |
Why?
| | Transcriptome | 2 | 2023 | 974 | 0.560 |
Why?
| | Glioma | 1 | 2022 | 397 | 0.560 |
Why?
| | Logistic Models | 12 | 2020 | 2064 | 0.560 |
Why?
| | Protein Conformation | 4 | 2015 | 930 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1465 | 0.550 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2113 | 0.550 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3292 | 0.550 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 96 | 0.540 |
Why?
| | Male | 73 | 2025 | 67718 | 0.530 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1740 | 0.520 |
Why?
| | Registries | 2 | 2024 | 2021 | 0.510 |
Why?
| | Markov Chains | 7 | 2017 | 124 | 0.490 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1950 | 0.480 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 158 | 0.480 |
Why?
| | Linear Models | 7 | 2018 | 851 | 0.480 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 474 | 0.470 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.460 |
Why?
| | Female | 59 | 2025 | 73162 | 0.450 |
Why?
| | Case-Control Studies | 10 | 2025 | 3546 | 0.450 |
Why?
| | Bayes Theorem | 7 | 2022 | 407 | 0.450 |
Why?
| | Protein Folding | 1 | 2016 | 282 | 0.450 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 89 | 0.450 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 400 | 0.440 |
Why?
| | Lupus Nephritis | 2 | 2025 | 63 | 0.440 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 683 | 0.430 |
Why?
| | Nerve Net | 3 | 2024 | 284 | 0.430 |
Why?
| | Statistics as Topic | 3 | 2025 | 316 | 0.420 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1079 | 0.420 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 118 | 0.420 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1436 | 0.410 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 171 | 0.410 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 172 | 0.410 |
Why?
| | India | 6 | 2023 | 193 | 0.400 |
Why?
| | Bias | 5 | 2022 | 221 | 0.400 |
Why?
| | Treatment Outcome | 9 | 2023 | 10821 | 0.390 |
Why?
| | Disease Progression | 15 | 2021 | 2755 | 0.390 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 57 | 0.390 |
Why?
| | Oncogenes | 1 | 2013 | 117 | 0.380 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 191 | 0.370 |
Why?
| | Animals | 33 | 2025 | 37011 | 0.370 |
Why?
| | Genome | 5 | 2017 | 292 | 0.360 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 528 | 0.360 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 6 | 0.360 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 599 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2521 | 0.350 |
Why?
| | Alzheimer Disease | 3 | 2015 | 559 | 0.340 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 17 | 0.340 |
Why?
| | Precision Medicine | 2 | 2025 | 426 | 0.340 |
Why?
| | Adenocarcinoma | 4 | 2017 | 937 | 0.340 |
Why?
| | Child, Preschool | 9 | 2025 | 11097 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2193 | 0.330 |
Why?
| | Antioxidants | 1 | 2014 | 577 | 0.330 |
Why?
| | Models, Neurological | 2 | 2024 | 259 | 0.330 |
Why?
| | Colorado | 6 | 2025 | 4521 | 0.320 |
Why?
| | Gene Expression | 3 | 2014 | 1505 | 0.320 |
Why?
| | Stem Cells | 3 | 2020 | 589 | 0.320 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 265 | 0.320 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 112 | 0.310 |
Why?
| | Signal Transduction | 10 | 2025 | 5096 | 0.310 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 30 | 0.310 |
Why?
| | Gene Dosage | 1 | 2010 | 148 | 0.310 |
Why?
| | Aged | 29 | 2024 | 23798 | 0.310 |
Why?
| | Risk Factors | 14 | 2025 | 10356 | 0.310 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 139 | 0.300 |
Why?
| | Middle Aged | 34 | 2024 | 33355 | 0.300 |
Why?
| | Child | 16 | 2025 | 22037 | 0.300 |
Why?
| | Liver Neoplasms | 1 | 2015 | 786 | 0.300 |
Why?
| | Protein Array Analysis | 8 | 2009 | 57 | 0.300 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 286 | 0.300 |
Why?
| | Proteomics | 5 | 2009 | 1113 | 0.290 |
Why?
| | Carcinoma | 2 | 2007 | 237 | 0.290 |
Why?
| | Emigration and Immigration | 1 | 2008 | 50 | 0.290 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.290 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.290 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 682 | 0.290 |
Why?
| | Probability | 3 | 2021 | 311 | 0.280 |
Why?
| | Chromosome Mapping | 6 | 2017 | 523 | 0.280 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 331 | 0.280 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1507 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 644 | 0.270 |
Why?
| | Research Design | 5 | 2021 | 1116 | 0.270 |
Why?
| | Flow Cytometry | 2 | 2022 | 1185 | 0.270 |
Why?
| | Tumor Burden | 1 | 2008 | 311 | 0.260 |
Why?
| | Adult | 27 | 2024 | 37821 | 0.260 |
Why?
| | Proteome | 3 | 2007 | 474 | 0.260 |
Why?
| | Pancreas | 2 | 2020 | 328 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 250 | 0.250 |
Why?
| | Monte Carlo Method | 4 | 2017 | 145 | 0.250 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1035 | 0.250 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 202 | 0.240 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 27 | 0.240 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1377 | 0.240 |
Why?
| | False Positive Reactions | 4 | 2012 | 117 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2482 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 95 | 0.230 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 504 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 538 | 0.230 |
Why?
| | Cell Nucleus | 2 | 2019 | 615 | 0.230 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2146 | 0.230 |
Why?
| | Replication Origin | 1 | 2004 | 19 | 0.230 |
Why?
| | Fever | 2 | 2023 | 307 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2420 | 0.220 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 65 | 0.220 |
Why?
| | Dengue Virus | 1 | 2024 | 48 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3722 | 0.220 |
Why?
| | Weather | 1 | 2024 | 42 | 0.220 |
Why?
| | Data Curation | 1 | 2024 | 17 | 0.220 |
Why?
| | Leukemia | 1 | 2006 | 238 | 0.220 |
Why?
| | Adolescent | 12 | 2025 | 21555 | 0.220 |
Why?
| | ROC Curve | 5 | 2020 | 547 | 0.210 |
Why?
| | Antigens | 1 | 2005 | 358 | 0.210 |
Why?
| | Dengue | 1 | 2024 | 77 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2007 | 770 | 0.210 |
Why?
| | Ligands | 2 | 2016 | 665 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1060 | 0.210 |
Why?
| | Cell Phone | 1 | 2024 | 75 | 0.210 |
Why?
| | Melanoma | 3 | 2005 | 758 | 0.210 |
Why?
| | Sample Size | 3 | 2008 | 118 | 0.210 |
Why?
| | Coculture Techniques | 1 | 2004 | 240 | 0.210 |
Why?
| | Histones | 4 | 2020 | 641 | 0.210 |
Why?
| | Staining and Labeling | 1 | 2023 | 146 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 1060 | 0.200 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 29 | 0.200 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.200 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 163 | 0.200 |
Why?
| | Carcinogens | 1 | 2003 | 123 | 0.200 |
Why?
| | Organometallic Compounds | 1 | 2023 | 111 | 0.200 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 176 | 0.200 |
Why?
| | Retina | 2 | 2016 | 298 | 0.200 |
Why?
| | Personality | 1 | 2004 | 131 | 0.200 |
Why?
| | Social Stigma | 1 | 2024 | 135 | 0.200 |
Why?
| | Emphysema | 1 | 2023 | 109 | 0.200 |
Why?
| | DNA, Complementary | 4 | 2007 | 269 | 0.200 |
Why?
| | Biomedical Research | 2 | 2025 | 689 | 0.190 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2249 | 0.190 |
Why?
| | Neuroimaging | 2 | 2015 | 291 | 0.190 |
Why?
| | Estrogens | 2 | 2019 | 361 | 0.190 |
Why?
| | Parasites | 1 | 2022 | 47 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 125 | 0.190 |
Why?
| | Construction Materials | 1 | 2021 | 15 | 0.190 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1255 | 0.180 |
Why?
| | Infant | 3 | 2024 | 9467 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2681 | 0.180 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.180 |
Why?
| | Brain Waves | 1 | 2021 | 34 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 501 | 0.180 |
Why?
| | Young Adult | 11 | 2024 | 13243 | 0.180 |
Why?
| | Zebrafish | 2 | 2016 | 496 | 0.180 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 50 | 0.180 |
Why?
| | Analysis of Variance | 4 | 2024 | 1324 | 0.180 |
Why?
| | Mutation, Missense | 2 | 2016 | 338 | 0.180 |
Why?
| | Receptors, Androgen | 2 | 2021 | 149 | 0.180 |
Why?
| | Epilepsy | 2 | 2021 | 334 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 658 | 0.180 |
Why?
| | Autoantibodies | 5 | 2020 | 1501 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 257 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1920 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 617 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 103 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 376 | 0.170 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 225 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 290 | 0.170 |
Why?
| | Peptides | 4 | 2007 | 986 | 0.170 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 76 | 0.170 |
Why?
| | Lymphocytes | 2 | 2023 | 395 | 0.170 |
Why?
| | RNA, Messenger | 8 | 2024 | 2838 | 0.160 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 102 | 0.160 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 162 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 117 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 186 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 834 | 0.160 |
Why?
| | Exome | 2 | 2018 | 231 | 0.160 |
Why?
| | Artificial Intelligence | 3 | 2008 | 275 | 0.160 |
Why?
| | Androgens | 3 | 2012 | 188 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 809 | 0.160 |
Why?
| | Hospital Mortality | 1 | 2024 | 902 | 0.160 |
Why?
| | Disease Reservoirs | 1 | 2019 | 21 | 0.160 |
Why?
| | Phosphorylation | 3 | 2019 | 1762 | 0.160 |
Why?
| | Tretinoin | 1 | 2020 | 123 | 0.160 |
Why?
| | Protein Binding | 5 | 2019 | 2229 | 0.160 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 533 | 0.160 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 40 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4031 | 0.150 |
Why?
| | Mice | 16 | 2025 | 17843 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 26 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 61 | 0.150 |
Why?
| | Disease | 1 | 2019 | 98 | 0.150 |
Why?
| | Pilot Projects | 2 | 2021 | 1703 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 76 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2901 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2615 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2024 | 803 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 96 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2020 | 170 | 0.150 |
Why?
| | Pituitary Gland | 2 | 2009 | 149 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 61 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 454 | 0.150 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 869 | 0.150 |
Why?
| | Nuclear Proteins | 2 | 2019 | 710 | 0.150 |
Why?
| | Genetic Markers | 3 | 2015 | 345 | 0.150 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 115 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2022 | 318 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 86 | 0.140 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 943 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 116 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 568 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 82 | 0.140 |
Why?
| | Pregnancy | 5 | 2019 | 6745 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 621 | 0.140 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 22 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 165 | 0.140 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 97 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5427 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 187 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 105 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 157 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 152 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 659 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 141 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 846 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1458 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2017 | 197 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 5 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 174 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 43 | 0.130 |
Why?
| | RNA, Viral | 2 | 2024 | 653 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 279 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 3 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 2 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 22 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 634 | 0.130 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 157 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2019 | 493 | 0.130 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 10 | 0.130 |
Why?
| | Mosquito Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 41 | 0.130 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 957 | 0.130 |
Why?
| | Anus Neoplasms | 1 | 2016 | 33 | 0.130 |
Why?
| | Oxides | 1 | 2016 | 45 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 269 | 0.130 |
Why?
| | Transcription Factors | 6 | 2017 | 1717 | 0.130 |
Why?
| | ErbB Receptors | 2 | 2012 | 616 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.130 |
Why?
| | Anesthesiologists | 1 | 2016 | 27 | 0.130 |
Why?
| | Heart Arrest | 1 | 2020 | 339 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 892 | 0.130 |
Why?
| | Berylliosis | 1 | 2018 | 185 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 576 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 218 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 379 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 403 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 90 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 123 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 367 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2021 | 495 | 0.120 |
Why?
| | Aged, 80 and over | 13 | 2022 | 7593 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 97 | 0.120 |
Why?
| | Cough | 2 | 2007 | 121 | 0.120 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1285 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 372 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 328 | 0.120 |
Why?
| | Oleic Acid | 1 | 2015 | 41 | 0.120 |
Why?
| | Proteolysis | 1 | 2016 | 180 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 3964 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 316 | 0.120 |
Why?
| | HIV Infections | 3 | 2022 | 2830 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 390 | 0.120 |
Why?
| | Air Pollution | 2 | 2017 | 315 | 0.120 |
Why?
| | Risk | 1 | 2017 | 905 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 446 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 799 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 400 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2183 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 1979 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 398 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 696 | 0.110 |
Why?
| | Time Factors | 5 | 2016 | 6817 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 39 | 0.110 |
Why?
| | Ants | 1 | 2014 | 25 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Catalysis | 2 | 2012 | 319 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 457 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 13 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2019 | 551 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 353 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 54 | 0.110 |
Why?
| | Benzothiazoles | 1 | 2014 | 33 | 0.110 |
Why?
| | Survival Rate | 4 | 2019 | 1980 | 0.110 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 88 | 0.110 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 16 | 0.110 |
Why?
| | Chromatography, Gel | 1 | 2014 | 127 | 0.110 |
Why?
| | Amphotericin B | 1 | 2013 | 31 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2857 | 0.110 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3420 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 89 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 233 | 0.110 |
Why?
| | Brain Diseases | 1 | 2015 | 141 | 0.110 |
Why?
| | Crystallization | 1 | 2014 | 144 | 0.110 |
Why?
| | Odds Ratio | 3 | 2020 | 1063 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 123 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 399 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5730 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 632 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5139 | 0.100 |
Why?
| | Estradiol | 2 | 2014 | 513 | 0.100 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.100 |
Why?
| | Interleukin-2 | 2 | 2025 | 456 | 0.100 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 299 | 0.100 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 7 | 0.090 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2024 | 104 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1040 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1271 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 79 | 0.090 |
Why?
| | Silver | 1 | 2012 | 39 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 917 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 107 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 425 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 868 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 195 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 13 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1163 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 15 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 974 | 0.090 |
Why?
| | Motion | 1 | 2012 | 101 | 0.090 |
Why?
| | Heme | 1 | 2012 | 79 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 92 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 13 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 11 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 93 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 982 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 101 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 226 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 344 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 227 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 704 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 179 | 0.090 |
Why?
| | Lung | 2 | 2023 | 4066 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3301 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 510 | 0.090 |
Why?
| | Chemokines | 1 | 2011 | 229 | 0.090 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 854 | 0.090 |
Why?
| | Vaccination | 1 | 2019 | 1398 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1123 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1083 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 152 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 91 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 567 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1059 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Prevalence | 2 | 2015 | 2719 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 414 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 299 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.080 |
Why?
| | Autoimmunity | 2 | 2025 | 907 | 0.080 |
Why?
| | CpG Islands | 2 | 2023 | 160 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 94 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 125 | 0.080 |
Why?
| | Peptide Library | 2 | 2007 | 88 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 948 | 0.080 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 53 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 775 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15628 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 102 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 203 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 623 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 46 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 38 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 127 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 328 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 87 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1586 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 696 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 234 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1012 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 32 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1312 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 395 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 35 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 48 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 190 | 0.070 |
Why?
| | Self Concept | 1 | 2009 | 260 | 0.070 |
Why?
| | Nails | 1 | 2007 | 13 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 351 | 0.070 |
Why?
| | Exercise | 1 | 2018 | 2024 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 118 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1286 | 0.070 |
Why?
| | Nepal | 2 | 2016 | 29 | 0.070 |
Why?
| | Genome, Bacterial | 2 | 2006 | 142 | 0.070 |
Why?
| | Genome, Human | 4 | 2016 | 424 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3708 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 74 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 58 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 123 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 336 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 42 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 66 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 64 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 586 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 30 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 32 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 614 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 26 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 146 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2557 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 40 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 189 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 59 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 381 | 0.060 |
Why?
| | United States | 7 | 2018 | 14696 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 168 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Family Characteristics | 2 | 2016 | 188 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 387 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 97 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 690 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 56 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 109 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 368 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 316 | 0.060 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 160 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 664 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 373 | 0.060 |
Why?
| | Poisson Distribution | 1 | 2004 | 75 | 0.060 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1061 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 268 | 0.060 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 55 | 0.060 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 19 | 0.060 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.060 |
Why?
| | Culture Techniques | 1 | 2004 | 81 | 0.060 |
Why?
| | Sputum | 1 | 2006 | 311 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 386 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 371 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 173 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 165 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 514 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 59 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2369 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 77 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 856 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 210 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 142 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1619 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 431 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 42 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 321 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 133 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 71 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 82 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 71 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1428 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 832 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 288 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 2290 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1548 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 175 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 137 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 137 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 322 | 0.050 |
Why?
| | Breast | 1 | 2003 | 153 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 849 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 37 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 130 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 135 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2197 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 107 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 328 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 253 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 392 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 95 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 723 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 184 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1167 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5792 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 29 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 54 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 177 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 38 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 283 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Seasons | 1 | 2024 | 546 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1099 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 24 | 0.050 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 36 | 0.040 |
Why?
| | Entropy | 1 | 2021 | 41 | 0.040 |
Why?
| | Japan | 1 | 2021 | 116 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 425 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2066 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 567 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 488 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 453 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 158 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 382 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 202 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 42 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 24 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 62 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 32 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 268 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 886 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 558 | 0.040 |
Why?
| | Policy | 1 | 2021 | 150 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 544 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 39 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 66 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 268 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 232 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 307 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 131 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 97 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 13 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 2870 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 15 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 517 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 23 | 0.040 |
Why?
| | Skin | 2 | 2017 | 751 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 438 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 24 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4295 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 99 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 344 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1310 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 720 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 790 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 439 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 218 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 334 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 266 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 242 | 0.040 |
Why?
| | Malaria | 1 | 2019 | 64 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 431 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 847 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 660 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 42 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 226 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 429 | 0.040 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 514 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 290 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 31 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 178 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1472 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3020 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 47 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 31 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 86 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 108 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 990 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 210 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 15 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 73 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 13 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 16 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 96 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 86 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 143 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 65 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 161 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 175 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 489 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 845 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 392 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 94 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 51 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 281 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 309 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 734 | 0.030 |
Why?
| | Family | 1 | 2019 | 667 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 205 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1192 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 165 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 308 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 972 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 71 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5676 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 187 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 314 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1066 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 141 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 22 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 853 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 342 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 97 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 674 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 29 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 39 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 435 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 237 | 0.030 |
Why?
| | Demography | 1 | 2014 | 292 | 0.030 |
Why?
| | North America | 1 | 2014 | 313 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 304 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 106 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 194 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 593 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2852 | 0.030 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 411 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 812 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2054 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2095 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 91 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 95 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 144 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 34 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 72 | 0.020 |
Why?
| | Methane | 1 | 2012 | 51 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 784 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 231 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 318 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7598 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 249 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 831 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1408 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1264 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 33 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2398 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 678 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 370 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 36 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 373 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 48 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1776 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 117 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 300 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 328 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2145 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1695 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 29 | 0.020 |
Why?
| | Genes | 1 | 2008 | 230 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 329 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 248 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 50 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 174 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 433 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 256 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 943 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 387 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 23 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 28 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 212 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 48 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1307 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 33 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 31 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 207 | 0.020 |
Why?
| | Television | 1 | 2007 | 75 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 807 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1092 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 129 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 100 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5772 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 78 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 190 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 93 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 92 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 170 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 511 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1242 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1357 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1332 | 0.020 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.020 |
Why?
| | Databases as Topic | 1 | 2005 | 66 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 60 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 77 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 51 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 60 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 366 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 94 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 55 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 42 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 357 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 429 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 198 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 149 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 349 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 91 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 262 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 27 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 554 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 19 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 86 | 0.010 |
Why?
| | Internet | 1 | 2007 | 656 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 66 | 0.010 |
Why?
| | California | 1 | 2003 | 425 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 204 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 604 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 191 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 555 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1618 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 646 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 889 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 948 | 0.010 |
Why?
| | RNA | 1 | 2005 | 924 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2039 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1129 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1866 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|